LIVE WEBINAR
Next-Generation DMPK Strategies for ADC Discovery
Explore practical DMPK and bioanalytical strategies for increasingly complex ADC modalities, from novel payloads to dual-payload architectures.
Antibody–drug conjugates continue to reshape targeted therapeutics, but their growing molecular complexity also raises the bar for discovery and early development. This webinar will highlight next-generation DMPK screening and advanced bioanalytical approaches that support faster, better-informed ADC candidate selection.
Key Topics
• DMPK screening strategies for novel payload chemistries
• Integrated early-stage ADC screening and decision-making
• Advanced bioanalysis for dual-payload ADCs
SPEAKER

Anna Li
VP, Head of XDC Discovery & DMPK, ICE Bioscience
Dr. Anna Li has over 18 years of industry experience in DMPK research, with deep expertise in small molecules, antibodies, ADCs, and PROTACs, giving her broad experience across diverse therapeutic modalities and enabling a comprehensive view of modality-specific DMPK challenges and development strategies.
Join us to learn how modern DMPK and bioanalytical strategies are helping advance the next wave of ADC discovery.
PREV:There's no more
NEXT:There's no more
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel:+86-10-67809840